Myology research highlights

RSS feed

Mutations in DPAGT1 cause a congenital myasthenic syndrome

Congenital myasthenic syndromes (CMS) are a group of inherited disorders that arise from impaired signal transmission at the neuromuscular synapse. They are characterized by fatigable muscle weakness. This is a heterogeneous group of disorders with 15 different genes implicated in the development of the disease. Using whole-exome sequencing the authors of the present study identified … [Read more]

Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at paediatric age

The molecular basis underlying the clinical variability in symptomatic Duchenne muscular dystrophy (DMD) carriers are still to be precised. This article describes 26 cases of early symptomatic DMD carriers followed in the French neuromuscular network. Clinical presentation, muscular histological analysis and type of gene mutation, as well as X-chromosome inactivation (XCI) patterns using DNA extracted … [Read more]

ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies

Dystroglycanopathies are a clinically and genetically diverse group of recessively inherited conditions ranging from the most severe of the congenital muscular dystrophies, Walker-Warburg syndrome, to mild forms of adult-onset limb-girdle muscular dystrophy. Their hallmark is a reduction in the functional glycosylation of α-dystroglycan, which can be detected in muscle biopsies. An important part of this … [Read more]

Mapping of a new locus for X-linked dominant Charcot Marie Tooth

Hereditary motor and sensory disorders of the peripheral nerve form one of the most common groups of human genetic diseases collectively called Charcot-Marie-Tooth (CMT) neuropathy. Using linkage analysis in a three-generation kindred, the authors of this study mapped a new locus for X-linked dominant CMT to chromosome Xp22.11. A microsatellite scan of the X chromosome … [Read more]

Widespread gene delivery to the spinal cord following intramuscular scAAV9-SMN injection

Researchers from the Institute of Myology recently demonstrated the remarkable efficiency of self-complementary (sc) AAV9 vectors for central nervous system (CNS) gene transfer following intravenous delivery in mice and larger animals. In this article, the same researchers investigated whether gene delivery to motor neurons (MNs) could also be achieved via intramuscular (i.m.) scAAV9 injection and … [Read more]

Pontocerebellar hypoplasia type 1: Clinical spectrum and relevance of EXOSC3 mutations

Pontocerebellar hypoplasia with spinal muscular atrophy, also known as PCH1, is a group of autosomal recessive disorders characterized by generalized muscle weakness and global developmental delay commonly resulting in early death. Gene defects had been discovered only in single patients until the recent identification of EXOSC3 mutations in several families with relatively mild course of … [Read more]

High risk of severe cardiac adverse events in patients with mitochondrial m.3243A>G mutation

This study aimed to determine the long-term incidence of cardiac life-threatening complications and death in patients with the m.3243A>G mutation, and to identify cardiac prognostic factors. Patients carrying the m.3243A>G mutation who were admitted to the Neuromuscular Disease Clinic of Pitié Salpêtrière Hospital between January 1992 and December 2010 were retrospectively included. Information relative to … [Read more]

Intravenous immunoglobulin for myasthenia gravis

Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). This is an update of a review first published in 2003 and last updated in 2007. The objectives of this update were to examine … [Read more]

Medical and surgical treatment for ocular myasthenia

Approximately 50% of people with myasthenia gravis present with purely ocular symptoms so called ocular myasthenia. Of these, 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review first published in 2006 and previously updated in 2008 and 2010. This update aimed to assess … [Read more]

Myotubular myopathy mice respond to modified myotubularin protein injections

No effective treatment exists for patients with X-linked myotubular myopathy (XLMTM), a fatal congenital muscle disease caused by deficiency of the lipid phosphatase, myotubularin. Mtm1δ4 and Mtm1 p.R69C mice model severely- and moderately-symptomatic XLMTM, respectively, due to differences in the degree of myotubularin deficiency. Contractile function of intact EDL and soleus muscles from Mtm1δ4 mice, … [Read more]